araag2/HINT huggingface dataset:
Clinical trial NCT02409355 (phase 3, status: terminated)
Conditions: non-small cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: atezolizumab, carboplatin, cisplatin, gemcitabine
SMILES: CCCNCC(O)COC1=C(C=CC=C1)C(=O)CCC1=CC=CC=C1, N[C@@H](CCCNC(N)=N)C(O)=O, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Reason stopped: 
    the study was closed due to low patient enrollment and the sponsor's decision to include
    patients with squamous nsclc into the go29431 study, nct02409342.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically or cytologically confirmed Stage IV squamous NSCLC

          -  Tumor programmed death-ligand 1 (PD-L1) expression, as determined by
             immunohistochemistry (IHC) assay of archival tumor tissue or tissue obtained at
             screening

          -  No prior treatment for Stage IV squamous NSCLC

          -  Measurable disease as defined by RECIST v1.1

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1

          -  Adequate hematologic and end-organ function

        Exclusion Criteria:

          -  Active or untreated central nervous system (CNS) metastases

          -  Untreated or inadequately treated spinal cord compression

          -  Leptomeningeal disease

          -  Uncontrolled pleural effusion, pericardial effusion, or ascites

          -  Uncontrolled tumor-related pain

          -  Uncontrolled hypercalcemia

          -  Any other malignancies within 5 years except those with negligible risk of metastasis
             or death

          -  Pregnant or lactating women

          -  Known hypersensitivity to any component of atezolizumab formulation or other study
             medication

          -  History of autoimmune disease except controlled, treated hypothyroidism or type I
             diabetes

          -  Prior allogeneic bone marrow or solid organ transplantation

          -  Positive human immunodeficiency virus (HIV) test

          -  Active hepatitis B or C

          -  Active tuberculosis

          -  Significant cardiovascular disease

          -  Severe infection or major surgery within 4 weeks prior to randomization

          -  Use of any approved anti-cancer therapy within 3 weeks prior to treatment

          -  Use of an investigational agent or participation in another clinical trial within 4
             weeks prior to randomization

          -  Exposure to oral or IV antibiotics within 2 weeks or live attenuated vaccines within 4
             weeks prior to randomization

          -  Prior treatment with cluster of differentiation (CD) 137 agonists or immune checkpoint
             blockade therapies, anti-programmed death-1 (anti-PD-1), and anti-PD-L1 therapeutic
             antibodies

          -  Treatment with immunostimulatory agents within 4 weeks or immunosuppressive agents
             within 2 weeks prior to randomization
Clinical trial NCT02411448 (phase 3, status: active, not recruiting)
Conditions: metastatic non-small cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: ramucirumab, placebo, erlotinib, gefitinib, osimertinib
SMILES: NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2, COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1, COC1=C(NC2=NC=CC(=N2)C2=CN(C)C3=C2C=CC=C3)C=C(NC(=O)C=C)C(=C1)N(C)CCN(C)C
Eligibility criteria:

        Inclusion Criteria:

          -  Cytologically or histologically confirmed diagnosis of Stage IV NSCLC as defined by
             the American Joint Committee on Cancer Staging Criteria for Lung Cancer (AJCC 7th
             edition 2009).

          -  Eligible for first-line treatment with erlotinib based on documented evidence of tumor
             harboring an activating EGFR mutation [exon 19 deletion or exon 21 (L858R)
             substitution mutation].

          -  Mandatory provision of adequate archived stage IV NSCLC tissue samples or tissue
             samples other than stage IV NSCLC may be acceptable (optional for part C).

          -  At least one measurable lesion.

          -  Life expectancy of at least 3 months.

        Exclusion Criteria:

          -  Known T790M EGFR mutation (not applicable for Part C Period 2).

          -  Known leptomeningeal carcinomatosis, uncontrolled/unstable spinal cord compression, or
             brain metastases.

          -  Serious illness or medical condition.

          -  Ongoing treatment with CYP3A4 inducers or strong inhibitors.

          -  Ongoing therapy with nonsteroidal anti-inflammatory drugs for more than 2 months.

          -  History of gross hemoptysis.

          -  Significant bleeding disorders.

          -  Radiologically documented evidence of major blood vessel invasion or encasement by
             cancer.

          -  Radiographic evidence of intratumor cavitation.

          -  History of gastrointestinal perforation within last 6 months.

          -  History of bowel obstruction, inflammatory enteropathy or extensive intestinal
             resection.

          -  History of any arterial thrombotic event within 6 months prior to enrollment.

          -  The participant has any known significant ophthalmologic abnormalities of the surface
             of the eye.
Clinical trial NCT02412111 (phase 3, status: completed)
Conditions: cystic fibrosis
ICD codes: E84.9, Z14.1, E84.0, E84.11, E84.8, E84.19, P09.4
Drugs: ivacaftor, tezacaftor/ivacaftor
SMILES: CC(C)(C)C1=CC(=C(O)C=C1NC(=O)C1=CNC2=CC=CC=C2C1=O)C(C)(C)C, CC(C)(CO)C1=CC2=CC(NC(=O)C3(CC3)C3=CC=C4OC(F)(F)OC4=C3)=C(F)C=C2N1C[C@@H](O)CO
Eligibility criteria:

        Inclusion Criteria:

          -  Heterozygous for F508del-CFTR mutation and a second CFTR allele with a gating defect
             that is clinically demonstrated to be ivacaftor responsive

          -  FEV1 ≥40% and ≤90% of predicted normal for age, sex, and height during screening

          -  Stable CF disease as judged by the investigator.

        Exclusion Criteria:

          -  History of any comorbidity that, in the opinion of the investigator, might confound
             the results of the study or pose an additional risk in administering study drug to the
             subject.

          -  Pregnant and nursing females (females of childbearing potential must have a negative
             pregnancy test at Screening and Week -4 Visits).

          -  Sexually active subjects of reproductive potential who are not willing to follow the
             contraception requirements
Clinical trial NCT02413398 (phase 3, status: completed)
Conditions: type 2 diabetes mellitus
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: dapagliflozin 10 mg, matching placebo for dapagliflozin
SMILES: CCOC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Female or male aged ≥18 years and <75 years.

          -  History of T2DM for more than 12 months.

          -  Inadequate glycemic control, defined as HbA1c ≥7.0% and ≤11%

          -  Stable anti-diabetic treatment regimen

          -  Renal impairment: CKD 3A

        Exclusion Criteria:

          -  Women of childbearing potential who are unwilling or unable to use an acceptable
             method to avoid pregnancy for the entire study period.

          -  History of diabetic ketoacidosis or hyperosmolar nonketotic coma.

          -  Severe uncontrolled hypertension defined as SBP ≥180 mmHg and/or Diastolic Blood
             Pressure (DBP) ≥110 mmHg

          -  Any of the following Cardiovascular (CV)/Vascular Diseases within 3 months of prior to
             signing the consent at visit 1:

        Myocardial infarction, Cardiac surgery or revascularization(CABG/PTCA), Unstable angina,
        Unstable heart failure (HF), HF New York Heart Association (NYHA) Class IV,Transient
        ischemic attack (TIA) or significant cerebrovascular disease, Unstable or previously
        undiagnosed arrhythmia.

          -  History of any biopsy or imaging verifying intercurrent kidney disease (such as
             glomerular nephritis or sign of renal artery stenosis) other than diabetic nephropathy
             or diabetic nephropathy with nephrosclerosis.

          -  Significant hepatic disease, including, but not limited to, chronic active hepatitis
             and/or severe hepatic insufficiency.

          -  Ongoing treatment with any SGLT2-inhibitor, GLP-1 analogue, or rapid/short acting
             insulins at screening.

          -  Participation in another clinical study with an Investigational Product (IP) during
             the last 30 days prior to signing the consent at visit 1.
Clinical trial NCT02414958 (phase 3, status: completed)
Conditions: diabetes mellitus, type 1
ICD codes: E10.65, E10.9, E10.21, E10.36, E10.41, E10.42, E10.44
Drugs: empagliflozin, empagliflozin, placebo
SMILES: CN(C)C(=N)NC(N)=N, CN(C)C(=N)NC(N)=N, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion criteria:

          -  Male or female patient receiving insulin for the treatment of documented diagnosis of
             Type 1 Diabetes Mellitus (T1DM) for at least 1 year at the time of Visit 1

          -  Fasting C-peptide value of < 0.7 ng/mL (0.23 nmol/L) at Visit 2 measured by the
             central laboratory

          -  Use of, and be willing, based on the Investigator's judgement, to continue throughout
             the duration of the trial, either:

               -  Multiple Daily Injections (MDI) of insulin consisting of at least one basal
                  insulin injection and at least three daily bolus injections OR

               -  Continuous Subcutaneous Insulin Infusion (CSII) of any insulin type, with at
                  least 5 months experience of using CSII prior to Visit 1

          -  HbA1c >/= 7.5% and </= 10.0% at Visit 5 measured by the central laboratory

          -  Age >/= 18 years at Visit 1

        Additional inclusion criteria may apply

        Exclusion criteria:

          -  History of Type 2 Diabetes Mellitus (T2DM), maturity onset diabetes of the young
             (MODY), pancreatic surgery or chronic pancreatitis

          -  Pancreas, pancreatic islet cells or renal transplant recipient

          -  T1DM treatment with any other antihyperglycaemic drug (e.g. metformin,
             alpha-glucosidase inhibitors, Glucagon-like-peptide 1 (GLP-1) analogues,
             Sodium-Glucose Co-Transporter (SGLT-2) inhibitors, pramlintide, inhaled insulin,
             pre-mixed insulins etc.) except subcutaneous basal and bolus insulin within 3 months
             prior to Visit 1

          -  Occurrence of severe hypoglycaemia involving coma/unconsciousness and/or seizure that
             required hospitalisation or hypoglycaemia-related treatment by an emergency physician
             or paramedic within 3 months prior to Visit 1 and until randomisation

          -  Occurence of Diabetic Ketoacidosis (DKA) within 3 months prior to Visit 1 and until
             randomisation

        Additional exclusion criteria may apply
Clinical trial NCT02415127 (phase 3, status: completed)
Conditions: friedreich's ataxia
ICD codes: G11.11
Drugs: interferon γ-1b, placebo
SMILES: CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Written informed consent and child assent, if applicable.

          -  FA confirmed by genetic testing with two expanded guanine-adenine-adenine (GAA)
             repeats.

          -  FA functional stage of >1 to <5 and ability to walk 25 feet with or without an
             assistive device.

          -  Male or female subject between the ages of 10 and 25 years, inclusive.

          -  If female, the subject is not pregnant or lactating or intending to become pregnant
             during the study, or within 30 days after the last dose of study drug. Female subjects
             of child-bearing potential must have a negative serum pregnancy test result at
             Screening, a negative urine pregnancy test result at Baseline, and agree to use a
             reliable method of contraception throughout the study and for 30 days after the last
             dose of study drug.

        Exclusion Criteria:

          -  Any unstable illness that in the investigator's opinion precludes participation in the
             study.

          -  Use of any investigational product within 30 days prior to randomization.

          -  A history of substance abuse.

          -  Presence of clinically significant cardiac disease (as determined by the investigator
             based on electrocardiogram [ECG] and echocardiogram results at Screening).
             Specifically, an ejection fraction of <40% or a prolonged QT interval (>50% of cycle
             duration) will result in exclusion. If the investigator notes any other clinically
             significant abnormalities on the ECG or echocardiogram, the subject may be eligible if
             they are provided clearance from a cardiologist.

          -  History of hypersensitivity to interferon (IFN)-ɣ or E. coli-derived products.

          -  Presence of moderate or severe renal disease (estimated creatinine clearance <50
             mL/min) or hepatic disease (aspartate aminotransferase [AST] or alanine
             aminotransferase [ALT] >2x the upper limit of normal) as evidenced by laboratory
             results at Screening.

          -  Clinically significant abnormal white blood cell count, hemoglobin, or platelet count
             as evidenced by laboratory test results at Screening.
Clinical trial NCT02419612 (phase 3, status: completed)
Conditions: diabetes
ICD codes: E23.2, N25.1, P70.2, O24.92, Z83.3, Z86.32, E10.65
Drugs: saxagliptin, dapagliflozin, glimepiride
SMILES: N[C@H](C(=O)N1[C@H]2C[C@H]2C[C@H]1C#N)C12CC3CC(CC(O)(C3)C1)C2, CN(C)C(=N)NC(N)=N, [H][C@]1(C)CC[C@@]([H])(CC1)N=C(O)NS(=O)(=O)C1=CC=C(CCN=C(O)N2CC(C)=C(CC)C2=O)C=C1
Eligibility criteria:

        For more information regarding BMS clinical trial participation, please visit
        www.BMSStudyConnect.com

        Inclusion Criteria:

          -  Subjects must be willing and able to give signed and dated written informed consent

          -  Patients with Type 2 diabetes mellitus (T2DM) with inadequate glycemic control

          -  Subjects should have been taking the same daily dose of metformin ≥ 1500 mg

          -  Fasting Plasma Glucose ≤ 270 mg/dL (≤15 mmol/L)

          -  Males and females, aged ≥18 years old at time of screening visit

          -  Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy
             test

          -  WOCBP and males must agree to follow instructions for method(s) of contraception for
             the duration of treatment with study drug

        Exclusion Criteria:

          -  Clinical diagnosis of type I diabetes

          -  History of diabetic ketoacidosis

          -  Cardiovascular/vascular diseases within 3 months of the enrollment

          -  Renal disease

          -  Hepatic diseases

          -  History of, or currently, acute or chronic pancreatitis

          -  Hematological and oncological disease/conditions

          -  Patients who have contraindications to therapy being studied

          -  Patients on weight loss program(s)

          -  Replacement or chronic systemic corticosteroid therapy
Clinical trial NCT02420262 (phase 3, status: completed)
Conditions: diabetes, diabetes mellitus, type 2
ICD codes: E23.2, N25.1, P70.2, O24.92, Z83.3, Z86.32, E10.65, E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: insulin degludec/liraglutide, insulin glargine, insulin aspart
SMILES: CN(C)C(=N)NC(N)=N, [Na+].[Na+].[O-]P([O-])(F)=O, [Na+].[Na+].[O-]P([O-])(F)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female, age at least 18 years at the time of signing informed consent

          -  Type 2 diabetes subjects (diagnosed clinically) at least 6 months prior to screening

          -  HbA1c (glycosylated haemoglobin) 7.0-10.0% [53mmol/mol-86mmol/mol] (both inclusive) by
             central laboratory analysis

          -  Current treatment with IGlar (insulin glargine) for at least 90 calendar days prior to
             screening

          -  Stable daily dose of IGlar between 20 units and 50 units (both inclusive) for at least
             56 calendar days prior to screening. Individual fluctuations of plus/minus 10% within
             the 56 calendar days prior to screening are acceptable, however on the day of
             screening total daily dose should be within the range of 20 units-50 units both
             inclusive

          -  Stable daily dose of metformin (at least 1500 mg or max tolerated dose) for at least
             90 calendar days prior to screening

          -  Body mass index (BMI) below or equal to 40 kg/m^2

        Exclusion Criteria:

          -  Treatment with any medication for the indication of diabetes or obesity other than
             stated in the inclusion criteria in a period of 90 calendar days before screening

          -  Anticipated initiation or change in concomitant medications in excess of 14 calendar
             days known to affect weight or glucose metabolism, such as weight loss/modifying
             (e.g.; sibutramine, orlistat, thyroid hormones, corticosteroids)

          -  Impaired liver function, defined as alanine aminotransferase (ALT) at least 2.5 times
             upper limit of normal

          -  Renal impairment eGFR (electronic case report form) below 60 mL/min/1.73 m^2 as per
             CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration)

          -  Screening calcitonin at least 50 ng/L

          -  History of pancreatitis (acute or chronic)

          -  Personal or family history of medullary thyroid carcinoma or multiple endocrine
             neoplasia type 2
Clinical trial NCT02421510 (phase 3, status: completed)
Conditions: type 1 diabetes mellitus
ICD codes: E10.65, E10.9, E10.21, E10.36, E10.41, E10.42, E10.44
Drugs: sotagliflozin, sotagliflozin, placebo
SMILES: CCOC1=CC=C(CC2=CC(=CC=C2Cl)[C@@H]2O[C@H](SC)[C@@H](O)[C@H](O)[C@H]2O)C=C1, CCOC1=CC=C(CC2=CC(=CC=C2Cl)[C@@H]2O[C@H](SC)[C@@H](O)[C@H](O)[C@H]2O)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Participant who gave written informed consent to participate in the study in
             accordance with local regulations.

          -  Adult participants 18 years and older with a diagnosis of T1D made at least 1 year
             prior to informed consent.

          -  Participants treated with insulin or insulin analog delivered via continuous
             subcutaneous insulin infusion (CSII) or multiple daily injections (MDI).

          -  Willing and were able to perform Self-monitoring of blood glucose (SMBG) and completed
             the study diary as required per protocol.

          -  At the Screening Visit, A1C was between 7.0% to 11.0%.

          -  Females of childbearing potential must use an adequate method of contraception and
             have a negative pregnancy test.

        Exclusion Criteria:

          -  Use of antidiabetic agent other than insulin or insulin analog at the time of
             screening.

          -  Use of sodium-glucose cotransporter (SGLT) inhibitors within 8 weeks prior to
             screening.

          -  Chronic systemic corticosteroid use.

          -  Type 2 diabetes mellitus (T2DM), or severely uncontrolled T1D as determined by the
             Investigator.
Clinical trial NCT02421588 (phase 3, status: completed)
Conditions: ovarian cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: lurbinectedin (pm01183), pegylated liposomal doxorubicin (pld), topotecan
SMILES: COC1=CC=C2NC3=C(CCN[C@]33CS[C@H]4[C@H]5[C@@H]6N(C)[C@@H](CC7=C6C(O)=C(OC)C(C)=C7)[C@H](O)N5[C@@H](COC3=O)C3=C4C(OC(C)=O)=C(C)C4=C3OCO4)C2=C1, [H]\C(=C(\[H])C1=CC=C(OC)C=C1)C(=O)OCC(CC)CCCC, CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=C(C=CC(O)=C4CN(C)C)N=C13)C2=O
Eligibility criteria:

        Inclusion Criteria:

          -  Age >/= 18 years

          -  Confirmed diagnosis of unresectable epithelial ovarian, fallopian tube or primary
             peritoneal cancer.

          -  Platinum-resistant disease (PFI: 1-6 months after last platinum-containing
             chemotherapy).

          -  Evaluable disease according to Response Evaluation Criteria in Solid Tumors (RECIST)
             v.1.1 criteria

          -  No more than three prior systemic chemotherapy regimens

          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) (ECOG PS) ≤ 2

          -  Adequate hematological, renal, metabolic and hepatic function

        Exclusion Criteria:

          -  Concomitant diseases/conditions: cardiac disease, immunodeficiency, chronic active
             hepatitis or cirrhosis, uncontrolled infection, bowel obstruction, any other major
             illness

          -  Prior treatment with PM01183, trabectedin, or with both PLD and topotecan.

          -  Requirement of permanent or frequent (i.e., once per week) external drainages within
             two weeks prior to randomization